Wednesday, February 4, 2026 at 2:19 PM
Boston Scientific reported a rise in fourth-quarter net income and sales, with a 16% increase in sales to $5.29 billion.
However, the company issued a soft forecast for the upcoming year, which may impact investor sentiment.
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
The company, which makes testing equipment for semiconductors and robotics, posted a fourth-quarter profit of $257.2 million, up from $146.3 million a year earlier.
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
GE HealthCare Technologies said profit fell in the fourth quarter, despite higher revenue, as the company continues to operate in what Chief Executive Peter Arduini called a dynamic macroeconomic environment.
